Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases
Open accessThe DOI matches its Crossref record; 147 of the 149 references it cites were found in a registry or an index.
Abstract
The polyglutamine (polyQ) diseases, such as Huntington’s disease and several types of spinocerebellar ataxias, are a group of inherited neurodegenerative diseases that are caused by an abnormal expansion of the polyQ tract in disease-causative proteins. Proteins with an abnormally expanded polyQ stretch undergo a conformational transition to β-sheet rich structure, which assemble into insoluble aggregates with β-sheet rich amyloid fibrillar structures and accumulate as inclusion bodies in neurons, eventually leading to neurodegeneration. Since misfolding and aggregation of the expanded polyQ proteins are the most upstream event in the most common pathogenic cascade of the polyQ diseases, they are proposed to be one of the most ideal targets for development of disease-modifying therapies for polyQ diseases. In this review, we summarize the current understanding of the molecular pathogenic mechanisms of the polyQ diseases, and introduce therapeutic approaches targeting misfolding and aggregation of the expanded polyQ proteins, which are not only effective on a wide spectrum of polyQ diseases, but also broadly correct the functional abnormalities of multiple downstream cellular processes affected in the aggregation process of polyQ proteins. We hope that in the near future, effective therapies are developed, to bring hope to many patients suffering from currently intractable polyQ diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similar to α-syn in PD and Tau in AD, polyQ-HTT aggregates exert toxic gain-of-function effects, forming β-sheet-rich structures that disrupt essential cellular pathways and cause neurotoxicity [169,170].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [170]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar to α-syn in PD and Tau in AD, polyQ-HTT aggregates exert toxic gain-of-function effects, forming β-sheet-rich structures that disrupt essential cellular pathways and cause neurotoxicity [169,170].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [170]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · cited 1×
“reported that treatment of cells with soluble oligomers of the polyQ protein results in significant cell death, which is inhibited by oligomer-specific antibodies, suggesting the potential cytotoxicity of the soluble intermediate species formed during the aggregation process [63].”
BackgroundMolecular chaperones in protein folding and proteostasis
Hartl, F. U., Bracher, A., & Hayer-Hartl, M. (2011) · Nature · doi:10.1038/nature10317 · Cited by 3,381 · cited 1×
“Among them, molecular chaperones have central roles in maintaining cellular proteostasis that assist refolding of misfolded proteins, and mediate degradation through autophagy and proteasome machinery [82].”
BackgroundAndrogen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
Spada, A. R. L., Wilson, E. M., Lubahn, D. B., Harding, A. E., & Fischbeck, K. H. (1991) · Nature · doi:10.1038/352077a0 · Cited by 2,784 · cited 13×
“So far, antisense oligonucleotides (ASO), short interfering RNAs (siRNA), and short hairpin RNAs (shRNA) have been employed to decrease the level of the disease-associated proteins of the polyQ diseases, including HD, SBMA, and several types of SCAs, and thus, to improve phenotypes of animal models for such diseases […”
BackgroundInfluentialAggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347 · cited 7×
“The polyQ-dependent pathogenesis has also recently been confirmed in a common marmoset transgenic model of SCA3, which was generated as the first primate model of the polyQ diseases [28].”
BackgroundInfluentialImpairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,181 · cited 1×
“Since formation of intranuclear inclusions in a transgenic mouse model of HD is followed by the onset of disease phenotypes [38], and the level of inclusion bodies formed in brains apparently correlates with the severity of polyQ disease phenotypes, they were considered to be responsible for neurodegeneration in the p…”
BackgroundInclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979 · cited 1×
“demonstrated that the levels of diffused polyQ proteins, rather than those of inclusions, accurately predict an increased risk of death [50].”
BackgroundAggresomes, inclusion bodies and protein aggregation
Kopito, R. R. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01852-3 · Cited by 1,921
CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1
Kawaguchi, Y., Okamoto, T., Taniwaki, M., Aizawa, M., Inoue, M., Katayama, S., Kawakami, H., Nakamura, S., Nishimura, M., Akiguchi, I., et al. (1994) · Nature Genetics · doi:10.1038/ng1194-221 · Cited by 1,753
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595 · cited 2×
“also reported that expression of a dominant negative mutant of ubiquitin-conjugating enzyme cell division cycle 34 (Cdc34) resulted in a significant decrease in intracellular inclusions formed in the cellular model of HD, but increased cytotoxicity [45].”
BackgroundHeat shock factors: integrators of cell stress, development and lifespan
Åkerfelt, M., Morimoto, R. I., & Sistonen, L. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2938 · Cited by 1,455 · cited 8×
“Subsequently, several groups revealed that overexpression of molecular chaperones including Hsp70 and Hsp40 in animal models such as Drosophila and mice expressing the expanded polyQ proteins, led to the suppression of inclusion formation, as well as to improvement of the typical disease-associated phenotypes, includi…”
BackgroundInfluentialTrinucleotide Repeat Disorders
Orr, H. T., & Zoghbi, H. Y. (2007) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.113042 · Cited by 1,368 · cited 1×
“So far, nine disorders are reported to belong to this type of diseases, including Huntington’s disease (HD), spinocerebeller ataxia (SCA) types 1, 2, 3, 6, 7 and 17, and dentatorubral pallidoluysian atrophy (DRPLA) (Table 1) [2].”
BackgroundScherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G. P., Davies, S. W., Lehrach, H., & Wanker, E. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80514-0 · Cited by 1,291 · cited 1×
“Wanker and coworkers performed ultrastructural analysis of these abnormal structures, and revealed the presence of amyloid-like fibrillar structures, not only in the aggregates formed in vitro, but also in the inclusion bodies in the brains of the transgenic mice models [37].”
BackgroundSarkar, S., Davies, J. E., Huang, Z., Tunnacliffe, A., & Rubinsztein, D. C. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609532200 · Cited by 1,142 · cited 1×
“Interestingly, it has been found that trehalose can also work as a potent activator of autophagy, and facilitates clearance of mutant huntingtin [110] and other aggregation-prone proteins associated with the neurodegenerative diseases [110–113].”
BackgroundAndrew, S. E., Paul Goldberg, Y., Kremer, B., Telenius, H., Theilmann, J., Adam, S., Starr, E., Squitieri, F., Lin, B., Kalchman, M. A., et al. (1993) · Nature Genetics · doi:10.1038/ng0893-398 · Cited by 1,129
Unstable expansion of CAG repeat in hereditary dentatorubral–pallidoluysian atrophy (DRPLA)
Koide, R., Ikeuchi, T., Onodera, O., Tanaka, H., Igarashi, S., Endo, K., Takahashi, H., Kondo, R., Ishikawa, A., Hayashi, T., et al. (1994) · Nature Genetics · doi:10.1038/ng0194-9 · Cited by 1,111
Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy
Ravikumar, B. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.9.1107 · Cited by 1,111
Trinucleotide repeat length instability and age of onset in Huntington's disease
Duyao, M., Ambrose, C., Myers, R., Novelletto, A., Persichetti, F., Frontali, M., Folstein, S., Ross, C., Franz, M., Abbott, M., et al. (1993) · Nature Genetics · doi:10.1038/ng0893-387 · Cited by 1,089
Reversal of Neuropathology and Motor Dysfunction in a Conditional Model of Huntington's Disease
Yamamoto, A., Lucas, J. J., & Hen, R. (2000) · Cell · doi:10.1016/s0092-8674(00)80623-6 · Cited by 1,067 · cited 1×
“generated a conditional model mice where expression of the expanded polyQ protein could be regulated through the control of a tetracyclin-based regulatory system, and demonstrated that turning off the expression of the polyQ protein in the symptomatic mice reduces inclusion bodies and ameliorates motor disturbance [11…”
BackgroundSteffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,062
Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases.
Perutz, M. F., Johnson, T., Suzuki, M., & Finch, J. T. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.12.5355 · Cited by 1,062 · cited 2×
“first reported that the chemically synthesized polyQ pepti e with a relatively short glutamine repeat (15 repeats of glutamines), under certain conditions, forms aggregates with β‐sheet rich structures [51].”
BackgroundNuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology
Gutekunst, C.-A., Li, S.-H., Yi, H., Mulroy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., & Li, X.-J. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02522.1999 · Cited by 914 · cited 1×
“For example, Li and colleagues examined brain tissues of HD patients at different stages, and found that only 1%–4% of striatal neurons have nuclear aggregates that are immunoreactive with the huntingtin antibody EM48, although the striatum is the most affected region in HD [42,43].”
BackgroundWarrick, J. M., Chan, H. Y. E., Gray-Board, G. L., Chai, Y., Paulson, H. L., & Bonini, N. M. (1999) · Nature Genetics · doi:10.1038/70532 · Cited by 830 · cited 1×
“Subsequently, several groups revealed that overexpression of molecular chaperones including Hsp70 and Hsp40 in animal models such as Drosophila and mice expressing the expanded polyQ proteins, led to the suppression of inclusion formation, as well as to improvement of the typical disease-associated phenotypes, includi…”
BackgroundIntranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3
Paulson, H. L., Perez, M. K., Trottier, Y., Trojanowski, J. Q., Subramony, S. H., Das, S. S., Vig, P., Mandel, J.-L., Fischbeck, K. H., & Pittman, R. N. (1997) · Neuron · doi:10.1016/s0896-6273(00)80943-5 · Cited by 830
Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease
Tanaka, M., Machida, Y., Niu, S., Ikeda, T., Jana, N. R., Doi, H., Kurosawa, M., Nekooki, M., & Nukina, N. (2004) · Nature Medicine · doi:10.1038/nm985 · Cited by 782 · cited 1×
“Trehalose, a natural disaccharide with chemical chaperone activity that binds to unfolded proteins and stabilizes their structure, has been reported to inhibit polyQ aggregation in vitro, and effectively improves disease phenotypes in HD model mice by oral administration [109].”
BackgroundKordasiewicz, H. B., Stanek, L. M., Wancewicz, E. V., Mazur, C., McAlonis, M. M., Pytel, K. A., Artates, J. W., Weiss, A., Cheng, S. H., Shihabuddin, L. S., et al. (2012) · Neuron · doi:10.1016/j.neuron.2012.05.009 · Cited by 770
Identification of a candidate therapeutic autophagy-inducing peptide
Shoji-Kawata, S., Sumpter, R., Leveno, M., Campbell, G. R., Zou, Z., Kinch, L., Wilkins, A. D., Sun, Q., Pallauf, K., MacDuff, D., et al. (2013) · Nature · doi:10.1038/nature11866 · Cited by 760
Cummings, C. J., Mancini, M. A., Antalffy, B., DeFranco, D. B., Orr, H. T., & Zoghbi, H. Y. (1998) · Nature Genetics · doi:10.1038/502 · Cited by 744 · cited 3×
“Moreover, it has been reported that the carboxy terminus of Hsc70-interacting protein (CHIP), a co-chaperone of Hsp70 that works as a E3 ubiquitin ligase, also suppresses polyQ aggregation and improves viability in the cells expressing polyQ proteins [85,86], and suppresses neurodegeneration in animal models of SCA1 a…”
BackgroundInactivation of the Mouse Huntington's Disease Gene Homolog Hdh
Duyao, M. P., Auerbach, A. B., Ryan, A., Persichetti, F., Barnes, G. T., McNeil, S. M., Ge, P., Vonsattel, J.-P., Gusella, J. F., Joyner, A. L., et al. (1995) · Science · doi:10.1126/science.7618107 · Cited by 723 · cited 2×
“A study using knock-out mice also demonstrated that heterozygous disruption of Hdh gene, a mouse homologue of human huntingtin gene, did not show apparent disease phenotypes, while homozygous disruption resulted in embryonic lethality, indicating that huntingtin has essential roles in the embryonic development, and lo…”
BackgroundHarper, S. Q., Staber, P. D., He, X., Eliason, S. L., Martins, I. H., Mao, Q., Yang, L., Kotin, R. M., Paulson, H. L., & Davidson, B. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501507102 · Cited by 682
Expanded Polyglutamine Protein Forms Nuclear Inclusions and Causes Neural Degeneration in Drosophila
Warrick, J. M., Paulson, H. L., Gray-Board, G. L., Bui, Q. T., Fischbeck, K. H., Pittman, R. N., & Bonini, N. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81200-3 · Cited by 668 · cited 9×
“From 46,000 compounds, we identified about 100 compounds that potently inhibit the polyQ aggregation in vitro (unpublished), some of which have currently been tested for their therapeutic effects using the polyQ models of Drosophila and mice.”
BackgroundInfluentialTrottier, Y., Lutz, Y., Stevanin, G., Imbert, G., Devys, D., Cancel, G., Saudou, F., Weber, C., David, G., Tora, L., et al. (1995) · Nature · doi:10.1038/378403a0 · Cited by 654 · cited 1×
“It has been reported that an antibody against the polyQ tract, 1C2, binds preferentially to longer polyQ repeats rather than shorter ones [64], implying that the polyQ tract would have different structures depending on its repeat length [65].”
BackgroundWhat is the role of protein aggregation in neurodegeneration?
Ross, C. A., & Poirier, M. A. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1742 · Cited by 604
SCA1 transgenic mice: A model for neurodegeneration caused by an expanded CAG trinucleotide repeat
Burright, E. N., Brent Clark, H., Servadio, A., Matilla, T., Feddersen, R. M., Yunis, W. S., Duvick, L. A., Zoghbi, H. Y., & Orr, H. T. (1995) · Cell · doi:10.1016/0092-8674(95)90273-2 · Cited by 595 · cited 1×
“Indeed, studies on animal models using mice [24,25], Drosophila [26] and C.”
BackgroundExpanded polyglutamine in the Machado–Joseph disease protein induces cell death in vitro and in vivo
Ikeda, H., Yamaguchi, M., Sugai, S., Aze, Y., Narumiya, S., & Kakizuka, A. (1996) · Nature Genetics · doi:10.1038/ng0696-196 · Cited by 545 · cited 1×
“Indeed, studies on animal models using mice [24,25], Drosophila [26] and C.”
BackgroundPivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders
Sánchez, I., Mahlke, C., & Yuan, J. (2003) · Nature · doi:10.1038/nature01301 · Cited by 503 · cited 1×
“Congo red was shown to reduce polyQ inclusions and improve motor deficits and survival in the model mice of HD via systemic administration [75], although the improvement has not been reproduced by other groups, probably due to the inability of this compound to cross the BBB [76].”
BackgroundWyttenbach, A. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.9.1137 · Cited by 494
Sittler, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1307 · Cited by 442 · cited 1×
“found that treatment of a Hsp90 inhibitor geldanamycin with the polyQ expressing cells led to induction of chaperones such as Hsp70, Hsp90, and Hsp40, resulting in significant inhibition of aggregation formation of the polyQ proteins, demonstrating for the first time that pharmacological induction of multiple chaperon…”
BackgroundBecher, M. W., Kotzuk, J. A., Sharp, A. H., Davies, S. W., Bates, G. P., Price, D. L., & Ross, C. A. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0168 · Cited by 433
Analysis of the Role of Heat Shock Protein (Hsp) Molecular Chaperones in Polyglutamine Disease
Chai, Y., Koppenhafer, S. L., Bonini, N. M., & Paulson, H. L. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-23-10338.1999 · Cited by 421 · cited 1×
“Subsequently, several groups revealed that overexpression of molecular chaperones including Hsp70 and Hsp40 in animal models such as Drosophila and mice expressing the expanded polyQ proteins, led to the suppression of inclusion formation, as well as to improvement of the typical disease-associated phenotypes, includi…”
BackgroundEhrnhoefer, D. E., Duennwald, M., Markovic, P., Wacker, J. L., Engemann, S., Roark, M., Legleiter, J., Marsh, J. L., Thompson, L. M., Lindquist, S., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl210 · Cited by 414
Molecular genetics: Unmasking polyglutamine triggers in neurodegenerative disease
Gusella, J. F., & MacDonald, M. E. (2000) · Nature Reviews Neuroscience · doi:10.1038/35039051 · Cited by 404
Identification and characterization of the gene causing type 1 spinocerebellar ataxia
Banfi, S., Servadio, A., Chung, M.-Y., Kwiatkowski, T. J., McCall, A. E., Duvick, L. A., Shen, Y., Roth, E. J., Orr, H. T., & Zoghbi, H. Y. (1994) · Nature Genetics · doi:10.1038/ng0894-513 · Cited by 373
Ordway, J. M., Tallaksen-Greene, S., Gutekunst, C.-A., Bernstein, E. M., Cearley, J. A., Wiener, H. W., Dure, L. S., Lindsey, R., Hersch, S. M., Jope, R. S., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80464-x · Cited by 370
Huntingtin Spheroids and Protofibrils as Precursors in Polyglutamine Fibrilization
Poirier, M. A., Li, H., Macosko, J., Cai, S., Amzel, M., & Ross, C. A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205809200 · Cited by 367 · cited 2×
“examined the aggregation of huntingtin fragment, and found that intermed at species uch as oligomers and protofibrils are produced before amyloid formation of the polyQ proteins, which are structurally similar to those of amyloid‐β and α‐synuclein formed in Alzheimer’s disease and Parkinson’s disease, implying the pat…”
BackgroundHuntington aggregates may not predict neuronal death in Huntington's disease.
Kuemmerle, S., Gutekunst, C., Klein, A., Li, X. J., Li, S. H., Beal, M. F., Hersch, S. M., & Ferrante, R. J. (1999) · PubMed · Cited by 362
Homozygotes for Huntington's disease
Wexler, N. S., Young, A. B., Tanzi, R. E., Travers, H., Starosta-Rubinstein, S., Penney, J. B., Snodgrass, S. R., Shoulson, I., Gomez, F., Arroyo, M. A. R., et al. (1987) · Nature · doi:10.1038/326194a0 · Cited by 355 · cited 1×
“In the case of HD, patients with homozygous mutations are reported to show apparently no more severe clinical phenotypes than typical patients with heterozygous mutation, suggesting that HD is caused by a true dominant mutation [8,9].”
BackgroundRAN Translation in Huntington Disease
Bañez-Coronel, M., Ayhan, F., Tarabochia, A. D., Zu, T., Perez, B. A., Tusi, S. K., Pletnikova, O., Borchelt, D. R., Ross, C. A., Margolis, R. L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.10.038 · Cited by 354
Amyloid-like Features of Polyglutamine Aggregates and Their Assembly Kinetics
Chen, S., Berthelier, V., Hamilton, J. B., O'Nuallai, B., & Wetzel, R. (2002) · Biochemistry · doi:10.1021/bi011772q · Cited by 348 · cited 2×
“Using synthetic polyQ peptides similar to those in the above report but with longer glutamine repeats, Wetzel and coworkers demonstrated that the polyQ peptides gradually undergo a conformational change from a solubilized form with random coil structure to insoluble amyloid-like fibrils with β-sheet structures [52].”
BackgroundA toxic monomeric conformer of the polyglutamine protein
Nagai, Y., Inui, T., Popiel, H. A., Fujikake, N., Hasegawa, K., Urade, Y., Goto, Y., Naiki, H., & Toda, T. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1215 · Cited by 333 · cited 4×
“Importantly, we demonstrated that conformational transition of Thio‐polyQ protein to a β‐sheet rich structure occurs in its monomeric state, followed by assembly into oligomers and insoluble amyloid fibrils [61].”
BackgroundInfluentialSelf-citationHuynh, D. P., Figueroa, K., Hoang, N., & Pulst, S.-M. (2000) · Nature Genetics · doi:10.1038/79162 · Cited by 330 · cited 1×
“Similar discrepancy was also reported in both patients and a transgenic mouse model of SCA2, where intranuclear inclusions were undetectable while disease phenotypes were exhibited [44].”
ResultHay, D. G. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh144 · Cited by 327 · cited 1×
“Radicicol, a fungal macrocyclic antibiotic that induces heat shock chaperones by a mechanism similar to that of geldanamycin, has also been shown to suppress polyQ aggregation in slice cultures from HD model mice (R6/2) [96].”
BackgroundJana, N. R., Dikshit, P., Goswami, A., Kotliarova, S., Murata, S., Tanaka, K., & Nukina, N. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412042200 · Cited by 323
Antisense oligonucleotide therapy for spinocerebellar ataxia type 2
Scoles, D. R., Meera, P., Schneider, M. D., Paul, S., Dansithong, W., Figueroa, K. P., Hung, G., Rigo, F., Bennett, C. F., Otis, T. S., et al. (2017) · Nature · doi:10.1038/nature22044 · Cited by 319
RNA toxicity is a component of ataxin-3 degeneration in Drosophila
Li, L.-B., Yu, Z., Teng, X., & Bonini, N. M. (2008) · Nature · doi:10.1038/nature06909 · Cited by 316
Huntingtin aggregates may not predict neuronal death in Huntington's disease
Kuemmerle, S., Gutekunst, C.-A., Klein, A. M., Li, X.-J., Li, S.-H., Beal, M. F., Hersch, S. M., & Ferrante, R. J. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6<842::aid-ana6>3.0.co;2-o · Cited by 308
Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron
Faber, P. W., Alter, J. R., MacDonald, M. E., & Hart, A. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.179 · Cited by 305 · cited 1×
“elegans [27] have demonstrated that expression of the expanded polyQ stretch alone, or artificial proteins fused with an expanded polyQ tract, results in progressive degeneration of neurons and motor disturbance, suggesting that the expanded polyQ tract is sufficient to cause typical phenotypes of the polyQ diseases.”
BackgroundAutophagic degradation of tau in primary neurons and its enhancement by trehalose
Krüger, U., Wang, Y., Kumar, S., & Mandelkow, E.-M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.009 · Cited by 297
Katsuno, M., Adachi, H., Doyu, M., Minamiyama, M., Sang, C., Kobayashi, Y., Inukai, A., & Sobue, G. (2003) · Nature Medicine · doi:10.1038/nm878 · Cited by 289 · cited 1×
“Subcutaneous injection of leuprorelin in a transgenic mouse model of SBMA decreased nuclear accumulation of mutant AR in muscle and spinal cord improved disease phenotypes such as motor dysfunction, and extended life span [141].”
BackgroundHarnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein
Bauer, P. O., Goswami, A., Wong, H. K., Okuno, M., Kurosawa, M., Yamada, M., Miyazaki, H., Matsumoto, G., Kino, Y., Nagai, Y., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1608 · Cited by 280 · cited 1×
“motifs, which is expected to specifically bind to proteins with the expanded polyQ tract and direct them to lysosomes through chaperone-mediated autophagy [116].”
BackgroundSelf-citationRodriguez-Lebron, E., Denovan-Wright, E. M., Nash, K., Lewin, A. S., & Mandel, R. J. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.05.006 · Cited by 275
Menzies, F. M., Huebener, J., Renna, M., Bonin, M., Riess, O., & Rubinsztein, D. C. (2010) · Brain · doi:10.1093/brain/awp292 · Cited by 262
Heiser, V., Scherzinger, E., Boeddrich, A., Nordhoff, E., Lurz, R., Schugardt, N., Lehrach, H., & Wanker, E. E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.110138997 · Cited by 262 · cited 2×
“Wanker and coworkers first reported that several compounds including Congo red effectively suppress the polyQ aggregation in vitro [68].”
BackgroundSoluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic
Takahashi, T., Kikuchi, S., Katada, S., Nagai, Y., Nishizawa, M., & Onodera, O. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddm311 · Cited by 258 · cited 3×
“In the subsequent studies, various techniques including atomic force microscopy (AFM), electron microscopy, and fluorescence correlation microscopy (FCS) have then been employed, not only to characterize the oligomers of the exp nded polyQ pr teins, but al o to nalyze the process of oligomer formation in vitro [54], i…”
BackgroundMethodResultSelf-citationAutophagy regulates the processing of amino terminal huntingtin fragments
Qin, Z.-H. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg346 · Cited by 254
Katsuno, M., Sang, C., Adachi, H., Minamiyama, M., Waza, M., Tanaka, F., Doyu, M., & Sobue, G. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506249102 · Cited by 237 · cited 1×
“mice, resulted in the up-regulation of various heat shock proteins in the central nervous system, leading to suppression of aberrant nuclear accumulation of the disease-associated androgen receptor and to amelioration of the polyQ-dependent neuromuscular phenotypes [98].”
BackgroundCHIP Suppresses Polyglutamine Aggregation and Toxicity In Vitro and In Vivo
Miller, V. M., Nelson, R. F., Gouvion, C. M., Williams, A., Rodriguez-Lebron, E., Harper, S. Q., Davidson, B. L., Rebagliati, M. R., & Paulson, H. L. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3001-05.2005 · Cited by 236 · cited 1×
“Moreover, it has been reported that the carboxy terminus of Hsc70-interacting protein (CHIP), a co-chaperone of Hsp70 that works as a E3 ubiquitin ligase, also suppresses polyQ aggregation and improves viability in the cells expressing polyQ proteins [85,86], and suppresses neurodegeneration in animal models of SCA1 a…”
BackgroundLegleiter, J., Mitchell, E., Lotz, G. P., Sapp, E., Ng, C., DiFiglia, M., Thompson, L. M., & Muchowski, P. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.093708 · Cited by 235 · cited 2×
“In the subsequent studies, various techniques including atomic force microscopy (AFM), electron microscopy, and fluorescence correlation microscopy (FCS) have then been employed, not only to characterize the oligomers of the exp nded polyQ pr teins, but al o to nalyze the process of oligomer formation in vitro [54], i…”
BackgroundMethodAutophagy induction by trehalose counter-acts cellular prion-infection
Aguib, Y., Heiseke, A., Gilch, S., Riemer, C., Baier, M., Ertmer, A., & Schätzl, H. M. (2009) · Autophagy · doi:10.4161/auto.5.3.7662 · Cited by 220
Identifying polyglutamine protein species in situ that best predict neurodegeneration
Miller, J., Arrasate, M., Brooks, E., Libeu, C. P., Legleiter, J., Hatters, D., Curtis, J., Cheung, K., Krishnan, P., Mitra, S., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.694 · Cited by 217
Takeuchi, T., Suzuki, M., Fujikake, N., Popiel, H. A., Kikuchi, H., Futaki, S., Wada, K., & Nagai, Y. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412651112 · Cited by 207 · cited 1×
“Using cellular and Drosophila models of polyQ diseases, we examined the molecular basis underlying this non-cell autonomous effect of Hsp40, and found that molecular chaperones including Hsp40 and Hsp70 are secreted via exosomes, one of the extracellular vesicles, and transmitted to the other cells, where they suppres…”
BackgroundSelf-citationHeiser, V., Engemann, S., Bröcker, W., Dunkel, I., Boeddrich, A., Waelter, S., Nordhoff, E., Lurz, R., Schugardt, N., Rautenberg, S., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182426599 · Cited by 205 · cited 1×
“Wanker’s group also developed an automated filter retardation assay and performed high-throughput screening using a large-scale chemical library (~184,000 compounds) to identify compounds that prevent aggregation formation of the expanded polyQ proteins [77].”
MethodHomozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course
Squitieri, F. (2003) · Brain · doi:10.1093/brain/awg077 · Cited by 203 · cited 1×
“However, in the later study, the disease-associated mutation in a double dose in homozygotes was reported to likely affect the disease progression but not the age of onset [10].”
BackgroundNagafuchi, S., Yanagisawa, H., Ohsaki, E., Shirayama, T., Tadokoro, K., Inoue, T., & Yamada, M. (1994) · Nature Genetics · doi:10.1038/ng1094-177 · Cited by 202
Lecerf, J.-M., Shirley, T. L., Zhu, Q., Kazantsev, A., Amersdorfer, P., Housman, D. E., Messer, A., & Huston, J. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.071058398 · Cited by 199
Fujikake, N., Nagai, Y., Popiel, H. A., Okamoto, Y., Yamaguchi, M., & Toda, T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710521200 · Cited by 199 · cited 1×
“We also tested a series of chaperone-inducing compounds in the fly models of the polyQ diseases, and found that 17-(allylamino)-17-demethoxygeldanamycin (17-AAG), a less toxic derivative of geldanamycin, has a high potency to suppress inclusion body formation as well as to inhibit progressive neuronal loss [99].”
BackgroundSelf-citationAl-Ramahi, I., Lam, Y. C., Chen, H.-K., de Gouyon, B., Zhang, M., Pérez, A. M., Branco, J., de Haro, M., Patterson, C., Zoghbi, H. Y., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601603200 · Cited by 198 · cited 13×
“So far, antisense oligonucleotides (ASO), short interfering RNAs (siRNA), and short hairpin RNAs (shRNA) have been employed to decrease the level of the disease-associated proteins of the polyQ diseases, including HD, SBMA, and several types of SCAs, and thus, to improve phenotypes of animal models for such diseases […”
BackgroundInfluentialDoyu, M., Sobue, G., Mukai, E., Kachi, T., Yasuda, T., Mitsuma, T., & Takahashi, A. (1992) · Annals of Neurology · doi:10.1002/ana.410320517 · Cited by 193
Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA
Wang, Y.-L., Liu, W., Wada, E., Murata, M., Wada, K., & Kanazawa, I. (2005) · Neuroscience Research · doi:10.1016/j.neures.2005.06.021 · Cited by 191
Katsuno, M., Banno, H., Suzuki, K., Takeuchi, Y., Kawashima, M., Yabe, I., Sasaki, H., Aoki, M., Morita, M., Nakano, I., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70182-4 · Cited by 189 · cited 1×
“However, a series of clinical trials of a randomized, placebo-controlled study for 48 weeks in SBMA patients showed no significant improvement in motor dysfunction, despite limited outcomes including suppression of AR accumulation and reduced serum level of testosterone [142,143].”
BackgroundBañez-Coronel, M., Porta, S., Kagerbauer, B., Mateu-Huertas, E., Pantano, L., Ferrer, I., Guzmán, M., Estivill, X., & Martí, E. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002481 · Cited by 188
Nagai, Y., Tucker, T., Ren, H., Kenan, D. J., Henderson, B. S., Keene, J. D., Strittmatter, W. J., & Burke, J. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10437 · Cited by 185 · cited 3×
“We also examined the kinetics of aggregation formation using a model polyQ protein fused with thioredoxin (Thio‐polyQ), and confirmed that soluble Thio‐polyQ proteins with the expanded polyQ repeat gradually form insoluble aggregates in a time‐, concentration‐, and repeat length‐dependent manner [60].”
MethodInfluentialSelf-citationIgarashi, S., Tanno, Y., Onodera, O., Yamazaki, M., Sato, S., Ishikawa, A., Miyatani, N., Nagashima, M., Ishikawa, Y., Sahashi, K., et al. (1992) · Neurology · doi:10.1212/wnl.42.12.2300 · Cited by 184
Colby, D. W., Chu, Y., Cassady, J. P., Duennwald, M., Zazulak, H., Webster, J. M., Messer, A., Lindquist, S., Ingram, V. M., & Wittrup, K. D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408134101 · Cited by 183
Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2
Miyazaki, Y., Adachi, H., Katsuno, M., Minamiyama, M., Jiang, Y., Huang, Z., Doi, H., Matsumoto, S., Kondo, N., Iida, M., et al. (2012) · Nature Medicine · doi:10.1038/nm.2791 · Cited by 170 · cited 1×
“In addition, several miRNAs have been identified that are able to reduce the expression level of the polyQ proteins by directly binding to 3’ untranslated regions of their mRNAs [128–130], or by indirect mechanisms [131,132].”
BackgroundLieberman, A. P., Yu, Z., Murray, S., Peralta, R., Low, A., Guo, S., Yu, X. X., Cortes, C. J., Bennett, C. F., Monia, B. P., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.008 · Cited by 169
Sathasivam, K., Lane, A., Legleiter, J., Warley, A., Woodman, B., Finkbeiner, S., Paganetti, P., Muchowski, P. J., Wilson, S., & Bates, G. P. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddp467 · Cited by 167 · cited 2×
“In the subsequent studies, various techniques including atomic force microscopy (AFM), electron microscopy, and fluorescence correlation microscopy (FCS) have then been employed, not only to characterize the oligomers of the exp nded polyQ pr teins, but al o to nalyze the process of oligomer formation in vitro [54], i…”
BackgroundMethodHSPB7 is the most potent polyQ aggregation suppressor within the HSPB family of molecular chaperones
Vos, M. J., Zijlstra, M. P., Kanon, B., van Waarde-Verhagen, M. A. W. H., Brunt, E. R. P., Oosterveld-Hut, H. M. J., Carra, S., Sibon, O. C. M., & Kampinga, H. H. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq398 · Cited by 165
Ranum, L. P. W., Chung, M., Banfi, S., Bryer, A., Schut, L. J., Ramesar, R., Duvick, L. A., McCall, A. E., Subramony, S. H., & Goldfarb, L. G. (1994) · PubMed Central · Cited by 164
Matsumura, R., Futamura, N., Fujimoto, Y., Yanagimoto, S., Horikawa, H., Suzumura, A., & Takayanagi, T. (1997) · Neurology · doi:10.1212/wnl.49.5.1238 · Cited by 163
Carra, S., Sivilotti, M., Chávez Zobel, A. T., Lambert, H., & Landry, J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi174 · Cited by 163
Fernández-Rhodes, L. E., Kokkinis, A. D., White, M. J., Watts, C. A., Auh, S., Jeffries, N. O., Shrader, J. A., Lehky, T. J., Li, L., Ryder, J. E., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70321-5 · Cited by 159 · cited 13×
“So far, antisense oligonucleotides (ASO), short interfering RNAs (siRNA), and short hairpin RNAs (shRNA) have been employed to decrease the level of the disease-associated proteins of the polyQ diseases, including HD, SBMA, and several types of SCAs, and thus, to improve phenotypes of animal models for such diseases […”
BackgroundInfluentialAdachi, H., Waza, M., Tokui, K., Katsuno, M., Minamiyama, M., Tanaka, F., Doyu, M., & Sobue, G. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1242-07.2007 · Cited by 157 · cited 13×
“So far, antisense oligonucleotides (ASO), short interfering RNAs (siRNA), and short hairpin RNAs (shRNA) have been employed to decrease the level of the disease-associated proteins of the polyQ diseases, including HD, SBMA, and several types of SCAs, and thus, to improve phenotypes of animal models for such diseases […”
BackgroundInfluentialPhase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy
Banno, H., Katsuno, M., Suzuki, K., Takeuchi, Y., Kawashima, M., Suga, N., Takamori, M., Ito, M., Nakamura, T., Matsuo, K., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21540 · Cited by 156 · cited 1×
“However, a series of clinical trials of a randomized, placebo-controlled study for 48 weeks in SBMA patients showed no significant improvement in motor dysfunction, despite limited outcomes including suppression of AR accumulation and reduced serum level of testosterone [142,143].”
BackgroundKhoshnan, A., Ko, J., & Patterson, P. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022631799 · Cited by 150
Olshina, M. A., Angley, L. M., Ramdzan, Y. M., Tang, J., Bailey, M. F., Hill, A. F., & Hatters, D. M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.084434 · Cited by 145 · cited 2×
“In the subsequent studies, various techniques including atomic force microscopy (AFM), electron microscopy, and fluorescence correlation microscopy (FCS) have then been employed, not only to characterize the oligomers of the exp nded polyQ pr teins, but al o to nalyze the process of oligomer formation in vitro [54], i…”
BackgroundMethodNagai, Y. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg144 · Cited by 144 · cited 1×
“Expression of QBP1 effectively suppresses polyQ inclusions as well as polyQ-induced neurodegeneration in Drosophila, supporting its therapeutic potential for the polyQ diseases [66].”
BackgroundSelf-citationSuppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies
Wolfgang, W. J., Miller, T. W., Webster, J. M., Huston, J. S., Thompson, L. M., Marsh, J. L., & Messer, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505321102 · Cited by 141 · cited 9×
“From 46,000 compounds, we identified about 100 compounds that potently inhibit the polyQ aggregation in vitro (unpublished), some of which have currently been tested for their therapeutic effects using the polyQ models of Drosophila and mice.”
BackgroundInfluentialEvaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models
Moore, L. R., Rajpal, G., Dillingham, I. T., Qutob, M., Blumenstein, K. G., Gattis, D., Hung, G., Kordasiewicz, H. B., Paulson, H. L., & McLoughlin, H. S. (2017) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2017.04.005 · Cited by 137
Muchowski, P. J., Ning, K., D'Souza-Schorey, C., & Fields, S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022628699 · Cited by 132 · cited 1×
“found the essential role of microtubule networks in inclusion body formation in a yeast model of HD, and demonstrated that treatment of yeast with chemicals that disrupt microtubule networks, however, facilitates the polyQ-induced toxicity: perturbation of microtubule-dependent intracellular trafficking results in sup…”
BackgroundTokui, K., Adachi, H., Waza, M., Katsuno, M., Minamiyama, M., Doi, H., Tanaka, K., Hamazaki, J., Murata, S., Tanaka, F., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn419 · Cited by 127 · cited 1×
“The other Hsp90 inhibitor, dimethylaminoethylamino-17-demethoxy-geldanamycin (17-DMAG), is shown to reduce nuclear accumulation of mutant androgen receptor (AR), and ameliorate motor impairment in the transgenic mouse model of SBMA by oral administration, although the therapeutic outcomes are considered to be attribut…”
BackgroundWong, H. K., Bauer, P. O., Kurosawa, M., Goswami, A., Washizu, C., Machida, Y., Tosaki, A., Yamada, M., Knöpfel, T., Nakamura, T., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn218 · Cited by 124 · cited 1×
“It has also been reported that activation of the cellular degradation systems such as autophagy and proteasome systems is effective for the treatment of polyQ diseases [102,103], as they can facilitate degradation of the expanded polyQ proteins and suppress polyQ-induced toxicity [104–106].”
BackgroundNucifora, L. G., Burke, K. A., Feng, X., Arbez, N., Zhu, S., Miller, J., Yang, G., Ratovitski, T., Delannoy, M., Muchowski, P. J., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.252577 · Cited by 121 · cited 2×
“In the subsequent studies, various techniques including atomic force microscopy (AFM), electron microscopy, and fluorescence correlation microscopy (FCS) have then been employed, not only to characterize the oligomers of the exp nded polyQ pr teins, but al o to nalyze the process of oligomer formation in vitro [54], i…”
BackgroundMethodHomozygote for Huntington disease.
Myers, R. H., Leavitt, J., Farrer, L. A., Jagadeesh, J., McFarlane, H. E., Mastromauro, C. A., Mark, R. J., & Gusella, J. F. (1989) · PubMed · Cited by 117
Wang, C.-E., Zhou, H., McGuire, J. R., Cerullo, V., Lee, B., Li, S.-H., & Li, X.-J. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200710158 · Cited by 117 · cited 1×
“, intrabodies, that have high affinity to the abnormally expanded polyQ proteins, have been reported to suppress formation of the polyQ aggregation and the polyQ-induced toxicity in the polyQ disease models of cells [69–71], Drosophila [72], and mice [73].”
BackgroundKeiser, M. S., Kordasiewicz, H. B., & McBride, J. L. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddv442 · Cited by 115
Silencing Mutant ATXN3 Expression Resolves Molecular Phenotypes in SCA3 Transgenic Mice
Rodríguez-Lebrón, E., Costa, M. D., Luna-Cancalon, K., Peron, T. M., Fischer, S., Boudreau, R. L., Davidson, B. L., & Paulson, H. L. (2013) · Molecular Therapy · doi:10.1038/mt.2013.152 · Cited by 113
Jodice, C., Malaspina, P., Persichetti, F., Novelletto, A., Spadaro, M., Giunti, P., Morocutti, C., Terrenato, L., Harding, A. E., & Frontali, M. (1994) · PubMed Central · Cited by 112
Legleiter, J. A., Lotz, G. P., Miller, J. M. L., Ko, J., Ng, C.-P., Williams, G. L., Finkbeiner, S. M., Patterson, P. H., & Muchowski, P. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.016923 · Cited by 109 · cited 1×
“It has been reported that an antibody against the polyQ tract, 1C2, binds preferentially to longer polyQ repeats rather than shorter ones [64], implying that the polyQ tract would have different structures depending on its repeat length [65].”
BackgroundQuigley, C. A. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.74.4.927 · Cited by 108 · cited 1×
“Indeed, loss of the disease-associated genes such as AR and huntingtin, a disease-causative gene of HD, shows no typical disease phenotypes likely observed in the patients of the polyQ diseases, ruling out a loss of function pathway for the disease pathogenesis [13,14].”
BackgroundRNA toxicity induced by expanded CAG repeats in Huntington's disease
Martí, E. (2016) · Brain Pathology · doi:10.1111/bpa.12427 · Cited by 108
Detection of Polyglutamine Protein Oligomers in Cells by Fluorescence Correlation Spectroscopy
Takahashi, Y., Okamoto, Y., Popiel, H. A., Fujikake, N., Toda, T., Kinjo, M., & Nagai, Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704789200 · Cited by 105 · cited 4×
“In the subsequent studies, various techniques including atomic force microscopy (AFM), electron microscopy, and fluorescence correlation microscopy (FCS) have then been employed, not only to characterize the oligomers of the exp nded polyQ pr teins, but al o to nalyze the process of oligomer formation in vitro [54], i…”
BackgroundMethodResultInfluentialSelf-citationInhibition of Rho kinases enhances the degradation of mutant huntingtin
Bauer, P. O., Wong, H. K., Oyama, F., Goswami, A., Okuno, M., Kino, Y., Miyazaki, H., & Nukina, N. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809229200 · Cited by 102 · cited 1×
“It has also been reported that activation of the cellular degradation systems such as autophagy and proteasome systems is effective for the treatment of polyQ diseases [102,103], as they can facilitate degradation of the expanded polyQ proteins and suppress polyQ-induced toxicity [104–106].”
BackgroundTomioka, I., Ishibashi, H., Minakawa, E. N., Motohashi, H. H., Takayama, O., Saito, Y., Popiel, H. A., Puentes, S., Owari, K., Nakatani, T., et al. (2017) · eNeuro · doi:10.1523/eneuro.0250-16.2017 · Cited by 91 · cited 1×
“The polyQ-dependent pathogenesis has also recently been confirmed in a common marmoset transgenic model of SCA3, which was generated as the first primate model of the polyQ diseases [28].”
BackgroundSelf-citationMolecular definition of the smallest region of deletion overlap in the Wolf-Hirschhorn syndrome.
Gandelman, K., Gibson, L. H., Meyn, M. S., & Yang-Feng, T. L. (1992) · Europe PMC (PubMed Central) · Cited by 85
Mitsui, K., Nakayama, H., Akagi, T., Nekooki, M., Ohtawa, K., Takio, K., Hashikawa, T., & Nukina, N. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09267.2002 · Cited by 81
An miRNA-mediated therapy for SCA6 blocks IRES-driven translation of the CACNA1A second cistron
Miyazaki, Y., Du, X., Muramatsu, S., & Gomez, C. M. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5660 · Cited by 81 · cited 1×
“In addition, several miRNAs have been identified that are able to reduce the expression level of the polyQ proteins by directly binding to 3’ untranslated regions of their mRNAs [128–130], or by indirect mechanisms [131,132].”
BackgroundIshihara, K., Yamagishi, N., Saito, Y., Adachi, H., Kobayashi, Y., Sobue, G., Ohtsuka, K., & Hatayama, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302975200 · Cited by 79
Allele-Specific Silencing of Mutant Huntingtin in Rodent Brain and Human Stem Cells
Drouet, V., Ruiz, M., Zala, D., Feyeux, M., Aurégan, G., Cambon, K., Troquier, L., Carpentier, J., Aubert, S., Mérienne, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099341 · Cited by 76
Hockly, E., Tse, J., Barker, A. L., Moolman, D. L., Beunard, J.-L., Revington, A. P., Holt, K., Sunshine, S., Moffitt, H., Sathasivam, K., et al. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.07.007 · Cited by 75 · cited 8×
“Based on structure-function relationship studies [138,139], together with the solution structure of polyQ proteins determined by NMR measurement [140], we are currently working on sequence optimization and derivatization of QBP1, as well as development of its small chemical analogues that are expected to efficiently p…”
BackgroundInfluentialOligonucleotide-based strategies to combat polyglutamine diseases
Fiszer, A., & Krzyżosiak, W. J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku385 · Cited by 74 · cited 1×
“Currently, gene silencing strategies have attracted much attention as a promising therapeutic approach for dominantly inherited neurodegenerative diseases including polyQ diseases [117,118].”
BackgroundTargeting CAG repeat RNAs reduces Huntington’s disease phenotype independently of huntingtin levels
Rué, L., Báñez-Coronel, M., Creus‐Muncunill, J., Giralt, A., Alcalá‐Vida, R., Mentxaka, G., Kagerbauer, B., Zomeño-Abellán, M. T., Aranda, Z., Venturi, V., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83185 · Cited by 72 · cited 1×
“Methods to allow allele-specific silencing by targeting disease-linked single-nucleotide polymorphisms (SNPs) [133–135] and specific conformations formed in abnormally expanded CAG repeats [136] have recently been tested, but these are still being developed (see review: [137]).”
BackgroundOnodera, O., Burke, J. R., Miller, S., Hester, S., Tsuji, S., Roses, A. D., & Strittmatter, W. J. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7337 · Cited by 66
Gomes, C., Escrevente, C., & Costa, J. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.03.065 · Cited by 66
Homozygous inheritance of the Machado‐Joseph disease gene
Lang, A. E., Rogaeva, E. A., Tsuda, T., Hutterer, J., & George‐Hyslop, P. S. (1994) · Annals of Neurology · doi:10.1002/ana.410360318 · Cited by 66 · cited 1×
“Gene dose effects were also reported in other polyQ diseases including SCA3 and SCA6 [11,12].”
BackgroundSilencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy
Sahashi, K., Katsuno, M., Hung, G., Adachi, H., Kondo, N., Nakatsuji, H., Tohnai, G., Iida, M., Bennett, C. F., & Sobue, G. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv300 · Cited by 57
Nagai, Y., & Popiel, H. A. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208786404164 · Cited by 57
Self-citationSaitoh, Y., Fujikake, N., Okamoto, Y., Popiel, H. A., Hatanaka, Y., Ueyama, M., Suzuki, M., Gaumer, S., Murata, M., Wada, K., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.590281 · Cited by 55
Self-citationPopiel, H. A., Nagai, Y., Fujikake, N., & Toda, T. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.06.015 · Cited by 51 · cited 1×
“However, QBP1 shows limited therapeutic effects on the mouse models of HD upon its peripheral administration [67], probably due to the poor efficiency of peptide-based drugs to pass through the blood-brain barrier (BBB).”
BackgroundSelf-citationHashizume, A., Katsuno, M., Suzuki, K., Hirakawa, A., Hijikata, Y., Yamada, S., Inagaki, T., Banno, H., & Sobue, G. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316015 · Cited by 51 · cited 1×
“Indeed, long-term treatment with this agent appears to delay functional decline, and shows effectiveness for patients [145].”
BackgroundChen, X., Wu, J., Luo, Y. M., Liang, X., Supnet, C. B., Kim, M. W., Lotz, G. P., Yang, G., Muchowski, P. J., Kodadek, T. J., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.06.010 · Cited by 46 · cited 6×
“The polyQ-dependent pathogenesis has also recently been confirmed in a common marmoset transgenic model of SCA3, which was generated as the first primate model of the polyQ diseases [28].”
BackgroundInfluentialPopiel, H. A., Takeuchi, T., Fujita, H., Yamamoto, K., Ito, C., Yamane, H., Muramatsu, S., Toda, T., Wada, K., & Nagai, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051069 · Cited by 45 · cited 1×
“We found that viral vector-mediated overexpression of Hsp40 in mouse brain results in improvement of motor disturbance and survival, as well as a significant reduction in inclusion body formation of polyQ proteins, demonstrating the effectiveness of a gene therapy approach using molecular chaperones for polyQ diseases…”
BackgroundSelf-citationmiR‐25 alleviates polyQ‐mediated cytotoxicity by silencing ATXN3
Huang, F., Zhang, L., Long, Z., Chen, Z., Hou, X., Wang, C., Peng, H., Wang, J., Li, J., Duan, R., et al. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.11.013 · Cited by 43
Nóbrega, C., Nascimento-Ferreira, I., Onofre, I., Albuquerque, D., Déglon, N., & Pereira de Almeida, L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100086 · Cited by 42
Tohnai, G., Adachi, H., Katsuno, M., Doi, H., Matsumoto, S., Kondo, N., Miyazaki, Y., Iida, M., Nakatsuji, H., Qiang, Q., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu066 · Cited by 42 · cited 1×
“Paeoniflorin, a major component of Paeonia plants, has been also shown to facilitate clearance of pathogenic AR by enhancing both autophagy and UPS, resulting in therapeutic improvement in behavioral and pathological impairments in SBMA model mice [115].”
BackgroundRen, H., Nagai, Y., Tucker, T. J., Strittmatter, W. J., & Burke, J. R. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5783 · Cited by 41 · cited 1×
“Based on structure-function relationship studies [138,139], together with the solution structure of polyQ proteins determined by NMR measurement [140], we are currently working on sequence optimization and derivatization of QBP1, as well as development of its small chemical analogues that are expected to efficiently p…”
Self-citationBonanomi, M., Natalello, A., Visentin, C., Pastori, V., Penco, A., Cornelli, G., Colombo, G., Malabarba, M. G., Doglia, S. M., Relini, A., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu373 · Cited by 40 · cited 1×
“redirect amyloid-like fibril formation of the polyQ proteins toward less-toxic off-pathway species that are poor in β-sheet structures with increasing solubility [80].”
BackgroundMiR-298 Counteracts Mutant Androgen Receptor Toxicity in Spinal and Bulbar Muscular Atrophy
Pourshafie, N., Lee, P. R., Chen, K., Harmison, G. G., Bott, L. C., Katsuno, M., Sobue, G., Burnett, B. G., Fischbeck, K. H., & Rinaldi, C. (2016) · Molecular Therapy · doi:10.1038/mt.2016.13 · Cited by 35
Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice
Wood, N. I., Pallier, P. N., Wanderer, J., & Morton, A. J. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.015 · Cited by 31 · cited 8×
“Based on structure-function relationship studies [138,139], together with the solution structure of polyQ proteins determined by NMR measurement [140], we are currently working on sequence optimization and derivatization of QBP1, as well as development of its small chemical analogues that are expected to efficiently p…”
BackgroundInfluentialVisentin, C., Pellistri, F., Natalello, A., Vertemara, J., Bonanomi, M., Gatta, E., Penco, A., Relini, A., GIOIA, L. D., Airoldi, C., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx211 · Cited by 27
Tailor-made RNAi knockdown against triplet repeat disease-causing alleles
Takahashi, M., Watanabe, S., Murata, M., Furuya, H., Kanazawa, I., Wada, K., & Hohjoh, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012153107 · Cited by 26
Structure–activity relationship study on polyglutamine binding peptide QBP1
Tomita, K., Popiel, H. A., Nagai, Y., Toda, T., Yoshimitsu, Y., Ohno, H., Oishi, S., & Fujii, N. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.12.018 · Cited by 25 · cited 1×
“Based on structure-function relationship studies [138,139], together with the solution structure of polyQ proteins determined by NMR measurement [140], we are currently working on sequence optimization and derivatization of QBP1, as well as development of its small chemical analogues that are expected to efficiently p…”
Self-citationRNA therapy for polyglutamine neurodegenerative diseases
Watson, L. M., & Wood, M. J. A. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2011.1 · Cited by 17 · cited 1×
“Methods to allow allele-specific silencing by targeting disease-linked single-nucleotide polymorphisms (SNPs) [133–135] and specific conformations formed in abnormally expanded CAG repeats [136] have recently been tested, but these are still being developed (see review: [137]).”
BackgroundRamos‐Martín, F., Hervás, R., Carrión‐Vázquez, M., & Laurents, D. V. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.06.025 · Cited by 15 · cited 1×
“Based on structure-function relationship studies [138,139], together with the solution structure of polyQ proteins determined by NMR measurement [140], we are currently working on sequence optimization and derivatization of QBP1, as well as development of its small chemical analogues that are expected to efficiently p…”
Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy
Hashizume, A., Katsuno, M., Suzuki, K., Hirakawa, A., Hijikata, Y., Yamada, S., Inagaki, T., Banno, H., & Sobue, G. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.08.588 · Cited by 1
Cited by
On the wrong DNA track: Molecular mechanisms of repeat-mediated genome instability
Khristich, A. N., & Mirkin, S. M. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev119.007678 · Cited by 289
Autophagy in Neurodegenerative Diseases: A Hunter for Aggregates
Park, H., Kang, J.-H., & Lee, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093369 · Cited by 207
Fluorescent Diagnostic Probes in Neurodegenerative Diseases
Zhou, J., Jangili, P., Son, S., Ji, M. S., Won, M., & Kim, J. S. (2020) · Advanced Materials · doi:10.1002/adma.202001945 · Cited by 204
Targeting Intrinsically Disordered Transcription Factors: Changing the Paradigm
Tsafou, K., Tiwari, P. B., Forman-Kay, J. D., Metallo, S. J., & Toretsky, J. A. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.04.008 · Cited by 112
The Multiple Roles of Autophagy in Neural Function and Diseases
Li, Y., Qin, Z., & Sheng, R. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01120-y · Cited by 118
“Cortical pyramidal neurons and striatal projection neurons specifically degenerate in HD brains due to the aggregation of the N-terminal mutant HTT and the development of intranuclear inclusion [91, 92].”
Background
Metadata
- Authors
- Takeuchi, T., & Nagai, Y.
- Affiliations
- The University of Osaka (JP)
- Corresponding author
- Takeuchi, Toshihide
- Nagai, Yoshitaka
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2017-10-11
- Volume
- 7
- Issue
- 10
- Pages
- 128
- ISSN
- 2076-3425 (ISSN-L)
- PMC
- PMC5664055
- OpenAlex
- W2762018403
- Cited by
- 71
- References
- 149
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 10 · 2023: 5 · 2022: 5 · 2021: 12 · 2020: 10 · 2019: 9 · 2018: 6
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Brain Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science
- Ministry of Health, Labour and Welfare
- Japan Agency for Medical Research and Development
- Japan Science and Technology Agency
- National Center of Neurology and Psychiatry
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- polyglutamine diseases, protein misfolding, protein aggregation, Huntington's disease, spinocerebellar ataxia, neurodegeneration, disease-modifying therapy, molecular pathogenesis, therapeutic target
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
